(north)-methanocarbathymidine profile

(North)-methanocarbathymidine is not a recognized chemical name or biological term. It's possible there's a typo or misunderstanding.

Here's why:

* **Methanocarbathymidine** is a possible chemical name, suggesting a modified thymidine base. However, north as a prefix is not standard in chemical nomenclature.
* **Thymidine** is a DNA nucleobase. Modifications to nucleobases are common in research and can affect DNA function.

**It's likely that the term you're looking for is a variation or misspelling of a known chemical name related to thymidine modifications.**

To help me understand what you're searching for, could you provide more context? For example:

* **Where did you encounter this term?** (e.g., research paper, textbook, website)
* **What is the context surrounding the term?** (e.g., DNA modification, genetic engineering, etc.)

With more information, I can help you find the correct term and explain its significance in research.

(north)-methanocarbathymidine: also called NMCT [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-[(1S,2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hexan-2-yl]thymine : A carbobicyclic compound that is bicyclo[3.1.0]hexane which is substituted at the 2-pro-S, 4-pro-S and 5-pro-R positions by thymin-1-yl, hydroxy, and hydroxymethyl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	445212
CHEMBL ID	146673
CHEBI ID	46026
MeSH ID	M0444329

Synonym
1-[(1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-bicyclo[3.1.0]hexanyl]-5-methyl-pyrimidine-2,4-dione
n-mct
north-methanocarbathymine
[(n)-methanocarba-t]
(n)-methanocarba-thymidine
1-[4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hex-2-yl]-5-methylpyrimidine-2,4(1h,3h)-dione
1E2K
1E2L
1-((1r,3s,4s,6s)-4-hydroxy-5-hydroxymethyl-bicyclo[3.1.0]hex-2-yl)-5-methyl-1h-pyrimidine-2,4-dione
1-((1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hexan-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
1-((1s,2s,4s,5r)-4-hydroxy-5-hydroxymethyl-bicyclo[3.1.0]hex-2-yl)-5-methyl-1h-pyrimidine-2,4-dione
bdbm50135091
n-methanocarbathymidine
(north)-methanocarbathymidine
north-methanocarbathymidine
CHEMBL146673 ,
chebi:46026 ,
1-[(1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-bicyclo[3.1.0]hexanyl]-5-methylpyrimidine-2,4-dione
1-[(1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hexan-2-yl]thymine
1-[(1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hex-2-yl]-5-methylpyrimidine-2,4(1h,3h)-dione
1-[(1's,2's,4's,5'r)-4'-hydroxy-5'-(hydroxymethyl)bicyclo[3.1.0]hexan-2'-yl]-5-methylpyrimidine-2,4(1h,3h)-dione
2,4(1h,3h)-pyrimidinedione, 1-(4-hydroxy-5-(hydroxymethyl)bicyclo(3.1.0)hex-2-yl)-5-methyl-, (1s-(1.alpha.,2.alpha.,4.beta.,5.alpha.))-
1-((1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)bicyclo(3.1.0)hex-2-yl)-5-methyl-2,4(1h,3h)-pyrimidinedione
2,4(1h,3h)-pyrimidinedione, 1-((1s,2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)bicyclo(3.1.0)hex-2-yl)-5-methyl-
2,4(1h,3h)-pyrimidinedione, 1-(4-hydroxy-5-(hydroxymethyl)bicyclo(3.1.0)hex-2-yl)-5-methyl-, (1s-(1alpha,2alpha,4beta,5alpha))-
156126-12-4
ltm5s02010 ,
unii-ltm5s02010
NOWRLNPOENZFHP-ARHDFHRDSA-N
Q27120643
DTXSID301028076

Excerpt	Reference	Relevance
" The objective of the present study was to assess the pharmacokinetic profile of (N)-MCT in C57BL/6 mice bearing nontransduced MC38 and MC38/HSV-tk tumors."	( Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene. Agbaria, R; Ben-Zvi, Z; Candotti, F; Elezra, M; Ford, H; Johns, DG; Marquez, VE; Morris, JC; Noy, R, 2002)	0.31

Excerpt	Reference	Relevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35

Excerpt	Reference	Relevance
" treatment regimens with (N)-MCT were directly compared during a vaccinia virus (IHD strain) infection, indicating that the nucleoside has good oral bioavailability in mice."	( Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Glazer, RI; Hurst, BL; Rahman, A; Sidwell, RW; Smee, DF; Wong, MH, 2007)	0.34

Class	Description
carbobicyclic compound	A bicyclic compound in which all the ring atoms are carbon.
primary alcohol	A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
secondary alcohol	A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
C-glycosyl pyrimidine
pyrimidone	A pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, THYMIDINE KINASE	Human alphaherpesvirus 1 strain 17	Ki	31.4500	11.4000	31.4500	51.5000	AID977610
Chain A, THYMIDINE KINASE	Human alphaherpesvirus 1 (Herpes simplex virus type 1)	Ki	31.4500	11.4000	31.4500	51.5000	AID977610
Thymidine kinase, cytosolic	Homo sapiens (human)	Ki	16.1000	0.0900	1.5213	7.0000	AID210688
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
nucleobase-containing compound metabolic process	Thymidine kinase, cytosolic	Homo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic process	Thymidine kinase, cytosolic	Homo sapiens (human)
thymidine metabolic process	Thymidine kinase, cytosolic	Homo sapiens (human)
thymidine biosynthetic process	Thymidine kinase, cytosolic	Homo sapiens (human)
protein homotetramerization	Thymidine kinase, cytosolic	Homo sapiens (human)
DNA synthesis involved in mitotic DNA replication	Thymidine kinase, cytosolic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
thymidine kinase activity	Thymidine kinase, cytosolic	Homo sapiens (human)
protein binding	Thymidine kinase, cytosolic	Homo sapiens (human)
ATP binding	Thymidine kinase, cytosolic	Homo sapiens (human)
zinc ion binding	Thymidine kinase, cytosolic	Homo sapiens (human)
identical protein binding	Thymidine kinase, cytosolic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Thymidine kinase, cytosolic	Homo sapiens (human)
cytosol	Thymidine kinase, cytosolic	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay ID	Title	Year	Journal	Article
AID85432	Inhibition constant against HSV-1 TK	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82232	Cytotoxic concentration for 50% inhibition of cell growth of HSV-1 infected HFF cells determined by VPR assay	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID28487	Catalytic rate constant was determined	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82249	Inhibitory concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID392511	Antiviral activity against Herpes simplex virus 1	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID235469	Selectivity index calculated as CC50/EC50 in the study of cytopathogenic effect by HSV-1	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82437	Selectivity index expressed as ratio of EC50 to that of CC50	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID91502	Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect in human skin fibroblast	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID91494	Cytotoxic concentration that produces 50% growth inhibition of human skin fibroblast in VPR assay	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82231	Cytotoxic concentration for 50% inhibition of cell growth of HSV-1 infected HFF cells determined by CPE assay	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82251	Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID235464	Selectivity index calculated as CC50/EC50 in the VPR assay of HSV-1	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82233	Cytotoxic concentration for 50% inhibition of cell growth of HSV-2 infected HFF cells determined by CPE assay	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID210686	Catalytic turnover constant against HSV-1 thymidine kinase	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82234	Cytotoxic concentration for 50% inhibition of cell growth of HSV-2 infected HFF cells determined by VPR assay	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82250	Inhibitory concentration for HSV-2 plaque reduction (VPR) by 50% in HFF cells	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID91499	Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) in human skin fibroblast	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID91498	Cytotoxic concentration that produces 50% growth inhibition of human skin fibroblast infected with HSV-1	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID82252	Inhibitory concentration required to reduce HSV-2 induced cytopathogenic effect (CPE) by 50 % in HFF cells	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID235466	Selectivity index calculated as CC50/EC50 in the VPR assay of HSV-2	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID91503	Inhibitory concentration required to reduce HSV-2 induced virus plaque reduction (VPR) in human skin fibroblast	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID210688	Binding affinity constant against HSV-1 thymidine kinase	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID91500	Inhibitory concentration required to reduce HSV-1 induced virus plaque reduction (VPR) in human skin fibroblast	2003	Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23	Synthesis and biological evaluation of 5-substituted derivatives of the potent antiherpes agent (north)-methanocarbathymine.
AID1811	Experimentally measured binding affinity data derived from PDB	2000	Biochemistry, Aug-08, Volume: 39, Issue:31	Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2000	Biochemistry, Aug-08, Volume: 39, Issue:31	Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (81.82)	29.6817
2010's	4 (18.18)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (4.55%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (95.45%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
cytosine [no description available]	2.03	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
triphosphoric acid triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure	2.01	1	acyclic phosphorus acid anhydride; phosphorus oxoacid
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	2.05	1	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.05	1	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	2.05	1	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.05	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	2.05	1	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
thymidine [no description available]	5.48	20	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	2.04	1	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
idoxuridine [no description available]	2.72	3	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.04	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
pyrimidine pyrimidine : The parent compound of the pyrimidines; a diazine having the two nitrogens at the 1- and 3-positions.	2.04	1	diazine; pyrimidines	Daphnia magna metabolite
benzohydroxamic acid [no description available]	2.05	1
n-hydroxyphthalimide N-hydroxyphthalimide: causes contact dermititis	2.05	1
toyocamycin Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.. toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group.	2.05	1	antibiotic antifungal agent; N-glycosylpyrrolopyrimidine; nitrile; ribonucleoside	antimetabolite; antineoplastic agent; apoptosis inducer; bacterial metabolite
deoxyuridine [no description available]	2.04	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.05	1	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acetylpyruvic acid acetylpyruvic acid: structure. acetylpyruvic acid : A dioxo monocarboxylic acid that is pentanoic acid carrying two oxo groups at positions 2 and 4.	2.05	1	beta-diketone; dioxo monocarboxylic acid	bacterial metabolite
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.05	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.05	1	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ribavirin Rebetron: Rebetron is tradename	2.05	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
fialuridine [no description available]	2.05	1
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	2.05	1	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	2.44	2	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
lamivudine [no description available]	2.05	1	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.05	1	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.05	1	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	2.05	1	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	2.05	1	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
amprenavir [no description available]	2.05	1	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	2.05	1	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
5-chloro-2'-deoxyuridine [no description available]	2.04	1
2-Oxo-4-phenylbutyric acid [no description available]	2.05	1	benzenes
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine [no description available]	2.05	1
clevudine [no description available]	2.05	1
lopinavir [no description available]	2.05	1	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	2.03	1	D-glucuronic acid	algal metabolite
4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine 4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine: structure given in first source; 5-bromotubercidin in which the ribose is replaced by 2-hydroxyethoxymethyl	2.05	1
cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine cyclic-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine: prodrug for HPMPC; specific name and structure not given in first source	2.05	1
bcx 1812 [no description available]	2.05	1	3-hydroxy monocarboxylic acid; acetamides; cyclopentanols; guanidines	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.03	1	divalent inorganic anion; phosphite ion
1-(benzenesulfonyl)indole [no description available]	2.05	1	sulfonamide
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.05	1	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
brivudine brivudine: anti-herpes agent	2.43	2
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.05	1	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
lamivudine triphosphate [no description available]	2.05	1
l 737126 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: structure given in first source; an inhibitor of HIV-1 reverse transcriptase	2.05	1
carbocyclic 5-iodo-2'-deoxyuridine [no description available]	2.01	1
ic9564 IC9564: betulinic acid derivative; structure in first source	2.05	1
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.05	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
2,5,6-trichloro-1-(ribofuranosyl)benzimidazole [no description available]	2.05	1
gw 257406x maribavir: has antiviral activity against human cytomegalovirus	2.05	1
cmx 001 [no description available]	2.05	1
favipiravir favipiravir : A member of the class of pyrazines that is pyrazine substituted by aminocarbonyl, hydroxy and fluoro groups at positions 2, 3 and 6, respectively. It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan.	2.05	1	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
6-phosphonylmethoxyethoxy-2,4-diaminopyrimidine [no description available]	2.05	1
4-phenyl-4-oxo-2-hydroxybuten-2-oic acid 2,4-dioxo-4-phenylbutanoic acid: structure in first source	2.05	1
2-hydroxy-4h-isoquinoline-1,3-dione 2-hydroxy-4H-isoquinoline-1,3-dione: structure in first source	2.05	1
benzoylacrylic acid benzoylacrylic acid: structure in first source	2.05	1
at 61 AT 61: a phenylpropenamide derivative; structure in first source	2.05	1
2',3'-didehydro-3'-deoxy-4'-ethynylthymidine 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine: a highly active anti-HIV agent; structure in first source	2.05	1
vicriviroc vicriviroc: structure in first source	2.05	1	(trifluoromethyl)benzenes
hcv 371 [no description available]	2.05	1
bms 806 BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002	2.05	1
flutimide flutimide: isolated from Delitschia confertaspora; selectively inhibits the transcriptase of influenza viruses; structure given	2.05	1
a 315675 [no description available]	2.05	1
rilpivirine [no description available]	2.05	1	aminopyrimidine; nitrile	EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor
bms 433771 [no description available]	2.05	1
oligonucleotides [no description available]	2.1	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.73	3	2-aminopurines; oxopurine	antimetabolite; antiviral drug
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	2.05	1	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	3.12	5	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.05	1	2-aminopurines; propane-1,3-diols	antiviral drug
cyclopropavir cyclopropavir: cyclopropavir is the (Z)-isomer; has antiviral activity; structure in first source	2.05	1

Condition	Relationship Strength	Studies
Recrudescence [description not available]	2.11	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.77	3
Genital Herpes [description not available]	2.11	1
Acute Disease Disease having a short and relatively severe course.	2.11	1
Herpes Genitalis Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.	2.11	1
Vaccinia The cutaneous and occasional systemic reactions associated with vaccination using smallpox (variola) vaccine.	2.95	4
Herpes Simplex Virus Infection [description not available]	2.95	4
Complications, Infectious Pregnancy [description not available]	2.06	1
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	2.95	4
Adenocarcinoma, Basal Cell [description not available]	2.01	1
Cancer of Colon [description not available]	2.01	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.01	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.01	1
Osteogenic Sarcoma [description not available]	2.02	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.02	1
Kaposi Sarcoma [description not available]	2.02	1
Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.	2.02	1
B Virus Infection [description not available]	2.03	1
Infections, Poxviridae [description not available]	2.03	1
Experimental Neoplasms [description not available]	2.03	1
Infections, Respiratory [description not available]	2.03	1
Cow Pox [description not available]	2.03	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	2.03	1

(north)-methanocarbathymidine

Description

Cross-References

Synonyms (31)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Drug Classes (5)

Protein Targets (3)

Inhibition Measurements

Biological Processes (6)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (25)

Research

Studies (22)

Market Indicators

Research Demand Index: 12.63

Study Types

(north)-methanocarbathymidine

Description

Cross-References

Synonyms (31)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Drug Classes (5)

Protein Targets (3)

Inhibition Measurements

Biological Processes (6)

Molecular Functions (5)

Ceullar Components (2)

Bioassays (25)

Research

Studies (22)

Market Indicators

Research Demand Index: 12.63

Study Types

Related Drugs (73)

Related Conditions (23)